Published in PLoS One on February 27, 2014
Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer | NCT01644968
Study of Immune Responses in Patients With Metastatic Melanoma | NCT01416844
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A (2015) 1.26
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res (2015) 1.12
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Emerging therapeutic agents for lung cancer. J Hematol Oncol (2016) 0.88
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy (2014) 0.87
Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med (2016) 0.84
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity (2016) 0.81
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med (2015) 0.80
Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine. Int J Mol Sci (2016) 0.79
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Int J Clin Oncol (2016) 0.79
Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia (2015) 0.79
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget (2015) 0.79
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol (2016) 0.78
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunology (2016) 0.77
Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8(+) T cells. Hum Vaccin Immunother (2016) 0.76
Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. Int J Cancer (2016) 0.75
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer (2017) 0.75
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75
Programmed death-1 (PD-1) rs2227981 C > T polymorphism is associated with cancer susceptibility: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. Front Immunol (2016) 0.75
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget (2016) 0.75
Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. Med Oncol (2017) 0.75
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. J Gynecol Oncol (2017) 0.75
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clin Cancer Res (2017) 0.75
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Cancer statistics, 2004. CA Cancer J Clin (2004) 15.72
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 4.06
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity (2001) 3.08
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 2.68
Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol (2010) 2.67
OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med (2008) 2.46
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05
The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol (2000) 2.04
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res (2013) 1.78
Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol (2000) 1.74
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One (2011) 1.73
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res (2012) 1.59
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res (2000) 1.46
The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol (2009) 1.39
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res (2013) 1.33
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol (2009) 1.32
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
Immunotherapy for ovarian cancer: what's next? J Clin Oncol (2010) 1.17
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol (2003) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res (2009) 1.08
Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest (2001) 1.06
New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol (2011) 1.06
Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother (2013) 1.04
Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res (2007) 1.02
Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother (2006) 1.01
Immunotherapy in ovarian cancer. Hum Vaccin Immunother (2012) 0.99
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med (2013) 0.94
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res (2010) 0.93
Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother (2012) 0.90
Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. J Soc Gynecol Investig (1998) 0.88
Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J Immunol (2013) 0.87
Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des (2012) 0.87